Trial Profile
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 08 Dec 2022 Planned End Date changed from 1 Oct 2023 to 1 Dec 2023.
- 11 Jan 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 11 Jan 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.